Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction–associated steatotic liver disease - Takeaways - MDSpire

Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction–associated steatotic liver disease

  • By

  • Rishi Chowdhary

  • Manjeet Kumar Goyal

  • Megh Patel

  • Rahul Chowdhary

  • Kirti Arora

  • Varun Mehta

  • Akash Batta

  • Omesh Goyal

  • Ashita Rukmini Vuthaluru

  • June 11, 2026

  • 0 min

Share

  • 1

    Sarcopenia prevalence among patients with metabolic dysfunction-associated steatotic liver disease (MASLD) has steadily increased from 2005 to 2024.

  • 2

    Sarcopenia is significantly associated with higher odds of cirrhosis, hepatic decompensation, and all-cause mortality in non-cirrhotic MASLD patients.

  • 3

    Patients with sarcopenia and MASLD face increased risks of major adverse cardiovascular events, including heart failure and ischemic heart disease.

  • 4

    Sarcopenia independently predicts adverse hepatic and cardiovascular outcomes, highlighting its importance in risk stratification for MASLD.

  • 5

    Early identification and management of sarcopenia in MASLD patients may improve long-term hepatic and cardiovascular outcomes.

Original Source(s)

Incidence, prevalence, and prognostic impact of sarcopenia on hepatic and cardiovascular outcomes in non-cirrhotic metabolic dysfunction–associated steatotic liver disease

  • by Rishi Chowdhary, Manjeet Kumar Goyal, Megh Patel, Rahul Chowdhary, Kirti Arora, Varun Mehta, Akash Batta, Omesh Goyal, Ashita Rukmini Vuthaluru

  • June 11, 2026

Related Content

Research on gastrointestinal polyp detection method based on improved YOLOv7

Sugar-Sweetened and Artificially Sweetened Beverages and Liver Cancer—A Hard Look at Soft Drinks

Optimizing gastric cancer treatment: the role of LODDs in lymph node staging